Erdanat 5 mg Erdanat 5 mg contains erdafitinib, a targeted anticancer medicine used to treat certain patients with advanced or metastatic urothelial cancer (bladder and urinary tract cancer) that has specific FGFR gene alterations. It works by blocking the activity of abnormal FGFR proteins that promote the growth and spread of cancer cells, helping to slow disease progression.

Effects & Benefits Helps slow the growth of cancer cells with FGFR gene alterations. Supports the treatment of advanced or metastatic urothelial cancer. Targets specific proteins involved in cancer cell growth. May help delay disease progression and improve treatment response. Offers a convenient oral treatment option as part of a specialist-directed cancer care plan. Possible Side Effects

Storage Store below 30°C in a cool and dry place. Keep the tablets in their original packaging until use. Protect from moisture, heat, and direct sunlight. Keep out of the reach of children. Dosage & Usage